Thiotepa

Generic Name
Thiotepa
Brand Names
Tepadina, Thiotepa Riemser
Drug Type
Small Molecule
Chemical Formula
C6H12N3PS
CAS Number
52-24-4
Unique Ingredient Identifier
905Z5W3GKH
Background

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication

ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions
Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Associated Therapies
-
Clinical Trials
Related News

CD34+ Transplants for Leukemia and Lymphoma

First Posted Date
2022-10-04
Last Posted Date
2024-11-25
Lead Sponsor
Guenther Koehne
Target Recruit Count
100
Registration Number
NCT05565105
Locations
🇺🇸

Baptist Health South Florida/Miami Cancer Institute, Miami, Florida, United States

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Phase 3
Recruiting
Conditions
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Busulfan
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Haploidentical Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Procedure: Matched Unrelated Donor Hematopoietic Cell Transplantation
Procedure: Lumbar Puncture
Drug: Melphalan
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Mycophenolate Mofetil
Procedure: Myeloablative Conditioning
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Rituximab
Procedure: T-Cell Depletion Therapy
Radiation: Total-Body Irradiation
Drug: Tacrolimus
Drug: Thiotepa
First Posted Date
2022-07-14
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
435
Registration Number
NCT05457556
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Phoenix Childrens Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

First Posted Date
2022-03-31
Last Posted Date
2022-07-01
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
64
Registration Number
NCT05303727
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

First Posted Date
2021-10-21
Last Posted Date
2024-02-20
Lead Sponsor
Stanford University
Target Recruit Count
40
Registration Number
NCT05088356
Locations
🇺🇸

Stanford University, Stanford, California, United States

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

First Posted Date
2021-08-26
Last Posted Date
2021-08-26
Lead Sponsor
Huiqiang Huang
Target Recruit Count
29
Registration Number
NCT05021770
Locations
🇨🇳

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

First Posted Date
2021-05-04
Last Posted Date
2024-04-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
59
Registration Number
NCT04872595
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Itacitinib for the Prevention of Graft Versus Host Disease

First Posted Date
2021-04-26
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
31
Registration Number
NCT04859946
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

First Posted Date
2021-01-13
Last Posted Date
2024-11-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
324
Registration Number
NCT04708054
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

First Posted Date
2020-12-24
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
160
Registration Number
NCT04684368
Locations
🇺🇸

University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

🇺🇸

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

🇦🇺

Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 151 locations

IS-free Treg HaploHCT

First Posted Date
2020-12-22
Last Posted Date
2024-12-04
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT04678401
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy